In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted solutions. We’ve made substantial advancements and improved access to precision oncology solutions globally. 

Here is a summary of select key achievements in 2024: 

FDA Approval of oncoReveal® CDx 
In April, Pillar Biosciences received FDA approval of the oncoReveal® CDx pan-cancer solid tumor IVD for general tumor profiling on the Illumina MiSeq™ Dx System. This approval enables localized testing in any NGS lab with an Illumina MiSeq™ Dx System, improving access to critical diagnostic testing and reducing time to treatment initiation. Learn More >>

oncoReveal® CDx CPT® Code Achievement 
In October, Pillar Biosciences received a CPT® code 0523U from the AMA for our FDA-approved oncoReveal® CDx multi-cancer IVD kit, marking a significant milestone in our commercialization efforts. Learn More >>

Launch of oncoReveal® Nexus
In August, Pillar Biosciences globally launched oncoReveal® Nexus, our research-use-only (RUO) NGS panel. This innovative panel assesses key driver genes for both hematological and solid tumor profiling in a single assay, with a rapid sample-to-report time accelerating time-to-treatment. Learn More >>

oncoReveal® Nexus Implemented at MSK as MSK-REACT 
By September, Memorial Sloan Kettering (MSK) Cancer Center implemented the oncoReveal® Nexus panel as a new rapid sequencing-based cancer panel to complement ongoing comprehensive genomic profiling (CGP). The assay, branded as MSK-REACT, utilizes oncoReveal® Nexus by masking two of the 21 genes in the panel and is available in separate reported formats for solid and hematological tumors. Learn More >>

Strategic Partnership with AstraZeneca 
September marked the beginning of our collaboration with AstraZeneca to expand access to liquid biopsy testing in European markets and the UK. This partnership aims to make tumor profiling more accessible through our rapid, affordable NGS testing solutions. Learn More >>

Expanded Collaboration with Illumina 
In October, Pillar Biosciences significantly broadened our partnership with Illumina, integrating an expanded range of oncoReveal® NGS panels into Illumina’s direct offerings. This strategic move positions Pillar’s advanced oncology panels as validated libraries on Illumina’s cutting-edge MiSeq i100 Series platform, enhancing the accessibility and power of targeted cancer genomic profiling. Learn More >>

Scientific Contributions and Advancements Presented at AMP 2024 
At the Association for Molecular Pathology (AMP) Annual Meeting, the Pillar Biosciences team and scientific collaborators collectively presented ten impactful studies and hosted three corporate workshops, showcasing our latest advancements in Next-Generation Sequencing (NGS) technology and oncology diagnostics. These studies and recorded workshop sessions are available in the News & Resources section of our website, pillarbiosci.com or by clicking here. Learn More >>

NGS Automation Scripts Developed and Validated on the Biomek NGeniuS
Throughout 2024, Pillar Biosciences developed and validated three NGS automation scripts on the Beckman Coulter Life Sciences Biomek NGeniuS Next Generation Library Prep System. This partnership aims to accelerate cancer research by combining Pillar’s NGS testing kits with Beckman Coulter’s automation capabilities. This partnership additionally aims to reduce error, assay costs, and hands-on time for NGS testing, making it more accessible and efficient for oncology researchers. Learn More >>

As we enter 2025, Pillar Biosciences remains committed to becoming the leading global provider of rapid, first-line NGS-kitted products to help accelerate the delivery of precision medicine.

We are excited to continue focusing on developing accessible, rapid, and clinically relevant NGS solutions that enable localized testing globally. In the new year, we look forward to expanding and updating our oncoReveal® product portfolio, delivering impactful webinars and presentations backed by scientific data, and contributing to the NGS technology and oncology diagnostics community.

We thank you for your continued support and look forward to another year of innovation and growth. 

About Pillar Biosciences

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar’s NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn.

More Information:
Brian Wright
602-540-9522
wrightb@pillarbiosci.com